BibbInstruments AB

BibbInstruments AB has a current liquidity position characterized by a current ratio of 2.03, indicating that the company holds twice as many current assets as current liabilities. However, the company reported negative operating cash flow of -1.572 million SEK and free cash flow of -4.404 million SEK, suggesting ongoing cash burn and limited ability to fund operations without external financing. The absence of long-term debt and a debt-to-equity ratio of 0.0 implies that the company is not leveraging debt to finance its operations, which may limit its growth potential.

Profitability metrics for BibbInstruments AB are negative, with a return on equity of -10.52% and a return on assets of -9.41%, both significantly below the industry median for Advanced Medical Equipment & Technology firms. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to produce profit.

The company's revenue is reported as 0.0 SEK, which suggests either a reporting anomaly or a very early-stage business with no revenue generation yet. There is no disclosed segment or geographic breakdown of revenue, making it difficult to assess the company's exposure to different markets or product lines.

Looking ahead, the company is expected to continue experiencing negative cash flows, with no clear indication of a turnaround in the near term. The absence of revenue and the ongoing cash burn raise concerns about the company's ability to scale or achieve profitability in the next fiscal year.

Risk factors for BibbInstruments AB include the high burn rate and lack of revenue, which could lead to liquidity constraints if external financing is not secured. The company has no immediate filing-based liquidity or dilution flags, and the dilution risk is currently assessed as low. However, the absence of long-term debt and the current equity base of 28.247 million SEK may not be sufficient to sustain operations without additional capital.

Recent filings and transcripts do not provide any new insights into the company's operations or strategic direction. The company appears to be in a pre-revenue phase, with no disclosed major product launches or customer contracts that could signal a path to profitability.

Revenue grew at a 123.7% CAGR over four years, indicating significant top-line expansion momentum for the company.

The company maintains zero long-term debt, resulting in a debt-to-equity ratio of 0.0 and eliminating leverage risk.

Dilution, liquidity, and credit risks are all assessed as low, providing a stable risk profile for investors.

The debt-to-equity ratio of 0.0 is above the cohort median of 0.11, highlighting a stronger capital structure.

The company reported a net loss of 14.61 million SEK in the latest fiscal year, demonstrating unprofitability.

Free cash flow remained negative at -17.61 million SEK, indicating the company continues to consume cash reserves.

Cash conversion of 0.53 is below the cohort median of 0.82, reflecting weaker operational cash generation.